Sienna Gestion Sells 566 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Key Points

• Sienna Gestion reduced its stake in Regeneron Pharmaceuticals by 5.8%, selling 566 shares in the first quarter, leaving it with approximately $5.65 million in holdings.
• Several brokerages have adjusted their price targets for Regeneron Pharmaceuticals, with Goldman Sachs lowering its target from $917 to $804, while BMO Capital Markets raised it from $600 to $640.
• Regeneron announced a quarterly dividend of $0.88 per share, with an annualized yield of 0.6%, payable on September 3rd to shareholders of record as of August 18th.

Sienna Gestion trimmed its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 5.8% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 9,165 shares of the biopharmaceutical company's stock after selling 566 shares during the period. Sienna Gestion's holdings in Regeneron Pharmaceuticals were worth $5,650,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its stake in shares of Regeneron Pharmaceuticals by 1.3% in the first quarter. Vanguard Group Inc. now owns 9,407,891 shares of the biopharmaceutical company's stock worth $5,966,767,000 after buying an additional 121,545 shares during the period. Capital International Investors boosted its holdings in Regeneron Pharmaceuticals by 41.6% during the 4th quarter. Capital International Investors now owns 4,736,929 shares of the biopharmaceutical company's stock valued at $3,373,859,000 after acquiring an additional 1,390,534 shares during the period. Price T Rowe Associates Inc. MD raised its position in Regeneron Pharmaceuticals by 63.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,085,447 shares of the biopharmaceutical company's stock valued at $1,485,527,000 after purchasing an additional 810,144 shares in the last quarter. Goldman Sachs Group Inc. raised its position in Regeneron Pharmaceuticals by 18.0% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,143,093 shares of the biopharmaceutical company's stock valued at $724,984,000 after purchasing an additional 174,056 shares in the last quarter. Finally, Northern Trust Corp raised its position in shares of Regeneron Pharmaceuticals by 14.8% in the 4th quarter. Northern Trust Corp now owns 1,054,829 shares of the biopharmaceutical company's stock worth $751,386,000 after acquiring an additional 136,184 shares in the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Stock Performance

Shares of Regeneron Pharmaceuticals stock traded up $14.44 during trading on Friday, hitting $580.41. 1,121,578 shares of the stock were exchanged, compared to its average volume of 985,857. The stock has a market capitalization of $61.52 billion, a price-to-earnings ratio of 14.63, a price-to-earnings-growth ratio of 1.93 and a beta of 0.33. The company has a current ratio of 4.60, a quick ratio of 3.72 and a debt-to-equity ratio of 0.09. The company has a fifty day moving average price of $544.21 and a 200-day moving average price of $594.90. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, topping the consensus estimate of $8.43 by $4.46. The business had revenue of $3,675,600 billion during the quarter, compared to the consensus estimate of $3.30 billion. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. Regeneron Pharmaceuticals's revenue was up 3.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $11.56 EPS. As a group, equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th will be issued a $0.88 dividend. The ex-dividend date of this dividend is Monday, August 18th. This represents a $3.52 dividend on an annualized basis and a yield of 0.6%. Regeneron Pharmaceuticals's payout ratio is currently 8.87%.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on REGN. Guggenheim boosted their target price on Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the stock a "buy" rating in a research note on Friday, August 1st. Argus cut Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Monday, June 30th. Royal Bank Of Canada increased their target price on Regeneron Pharmaceuticals from $688.00 to $695.00 and gave the company a "sector perform" rating in a report on Monday, August 4th. Robert W. Baird cut their price target on Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating for the company in a report on Friday, April 25th. Finally, UBS Group restated a "neutral" rating on shares of Regeneron Pharmaceuticals in a report on Friday, August 1st. One analyst has rated the stock with a sell rating, seven have given a hold rating, seventeen have assigned a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat, Regeneron Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus price target of $838.00.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.